Targeted Relief

Real Impact

Global Potential

We believe there is a unique opportunity to create something meaningful together. By addressing a clear and widespread unmet need in oral care, OriPatch combines scientific innovation with real patient impact.

Together with the right partners, we aim to improve everyday quality of life while building a scalable and globally relevant solution.

Let’s create something meaningful together.

Your Questions, Answered

  • OriPatch addresses the need for effective and targeted pain relief for oral ulcers and lesions. Current treatments, such as gels and ointments, often spread in the mouth and provide limited relief. OriPatch offers a more precise, protective and user-friendly solution.

  • OriPatch is based on a proprietary two-layer polymer technology that enables adhesion to wet oral tissue. Compared to existing products, it offers:

    • Higher precision

    • Improved user comfort

    • Better protection of the wound

    • No need for removal after use

  • Oral ulcers affect approximately 15–20% of the global population. This represents a significant and recurring market opportunity. In addition, OriPatch can be used for other oral conditions such as wounds from orthodontics, prosthetics, or accidental bites, with selfhealing ulcers <10mm.

  • 2019
    OriPatch was founded in Kristiansand, Norway, with the ambition to develop a new solution for painful oral ulcers.

    September 2020
    Grant from Forskningsmobilisering Agder: NOK 0.3 million.

    December 2020
    Market clarification grant from Innovation Norway: NOK 0.15 million.

    June 2021
    First patent application filed.

    September 2021
    Grant from Regional Research Fund Agder (pre-project): NOK 0.3 million.

    March 2022
    Commercialisation grant from Innovation Norway: NOK 0.55 million.

    July 2022
    International patent application (PCT) filed.

    September 2022
    First private investment secured: NOK 3 million.
    Trademark registered in Norway, the EU and the UK.

    January 2023
    Grant from Regional Research Fund Agder (main project): NOK 1.75 million.

    September 2023
    Trademark registered in the United States.
    Letter of intent signed with Oris Dental.

    2024–2025
    Strengthening of the team with R&D and business advisor Ralf Schmidt.

    February 2025
    Grant commitment from Innovation Norway (Innovation Contract): NOK 8.9 million.

    December 2025
    Commercial agreement secured with Oris Dental.

    February 2026
    Oversubscribed funding round completed: NOK 13 million.

    2027 (planned)
    Planned launch of first MDR-approved medical device.

  • OriPatch is targeting launch of its first MDR-approved product in 2027.

  • OriPatch combines a large unmet medical need with a scalable product and strong scientific foundation. With validated technology, international potential, and an experienced team, the company is well-positioned for growth in the global oral care market.

  • If you are interested in learning more, we would be delighted to hear from you and discuss potential investment opportunities.

    Please send us an email, and we will come back to you shortly.

Media Coverage

Learn more